In a report released today, Drew Jones from Stephens reiterated a Buy rating on Cambrex Corp (NYSE: CBM), with a price target of $72. The company’s shares opened today at $66.15, close to its 52-week high of $67.75.
According to TipRanks.com, Jones is a 4-star analyst with an average return of 16.9% and a 72.0% success rate. Jones covers the Healthcare sector, focusing on stocks such as Bio-Techne Corporation, Orasure Technologies, and Pacific Biosciences.
Currently, the analyst consensus on Cambrex Corp is a Moderate Buy with an average price target of $72.
See today’s analyst top recommended stocks >>
The company has a one-year high of $67.75 and a one-year low of $42.55. Currently, Cambrex Corp has an average volume of 405.2K.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics. It supplies to innovator and generic pharmaceutical companies.
